Ind-Swift Laboratories Ltd is a part of the Ind-swift Group and is based at Chandigarh, India. The company manufactures and sells active pharmaceutical ingredients (API). Their product pipeline consists of 25 products, which includes drugs, which include Clarithromycin (Macrolide antibiotic), Atorvastatin (anticholestrol), Fexofenadine (antihistamine), Clopidogrel (anticholestrol), Nitazoxanide (antidiarrheal), Pioglitazone (antidiabetic), Letrozole and Anastrozole (anticancer), Venlafaxine (antidepressants) and Quetipine and Aripirazole (antipsychotic). The company has one subsidiary namely, Ind-Swift Laboratories Inc in USA.

Ind-Swift Laboratories Ltd was formally created and deployed as a legal entity in the year 1995 as a joint venture between Ind-Swift Ltd and Punjab State Industrial Development Corporation. Later, Ind-Swift purchased Punjab State Industrial Development Corporation equity to emerge as a single largest shareholder in the company. The company commenced their production in the year 1997. Over a short period, the company has emerged as a respectable and dependable supplier of Bulk-Actives in more than 40 countries.

In the year 1997, the company went public and concentrated on the manufacture of Active Pharmaceutical Ingredients (API). In the year 1998-99, they formally introduced two molecules, Clarithromycin and Roxithromycin. Their in-house R&D successfully engineered Clarithromycin Granules for the first time in India.

In the year 2000, the company successfully engineered a new drug namely, Astrovastatin. In addition, they broadened its footprint operations into into an agreement with eight international pharmaceutical companies to source their requirements for Clarithromycin Fexofenadine Roxithromycin and Candesartan from the company.

During the year 2003-04, the company increased the production capacity of bulk drugs/ intermediates from 81.18 TPA to 120 TPA. In addition, they commissioned the granulation facility as per CGMP standards. They formally introduced four new products namely, Acamprosate (alcohol abstinence), Ezetimibe (anti-hyperlipidemic), Anastrazole (oncology) and Nitazoxanide (anti-diarroheal).

In January 2, 2004, the company incorporated a wholly owned subsidiary, namely Ind-Swift Laboratories Inc in USA to strengthen the company's presence in contract research and manufacturing services. In June 2004, the subsidiary company commenced their operations.

During the year 2004-05, the company broadened its footprint the production capacity of bulk drugs/ intermediates from 120 TPA to 150 TPA. They commissioned waste heat recovery unit to reduce energy costs. They opened and office in China to facilitate the import of raw materials. The company introduced five new products in the market.

During the year 2005-06, the company completed and commissioned their new plant at Samba in Jammu & Kashmir to manufacture products for the domestic markets. Also, they created and deployed a new state of the art Research & Development center at Mohali, Punjab with an investment of USD 5 million. They increased the production capacity of bulk drugs/ intermediates by 87.03 TPA to 237.03 TPA.

During the year, the company formally introduced new products namely, Letrozole, Anastrozole (Anti-Cancer) Venlafaxine (Anti-Depressants) Lavofloxacin (Anti-Biotic) Quetipine & Aripirazole (Anti-Pshychotic) in the market. They broadened its footprint operations into into a joint venture with Farayand Chemi Hakim Co, a private joint stock company registered under the law of Iran to strategic emphasis on the marketing of the products in Middle East & Iran.

During the year 2006-07, the company broadened its footprint the production capacity of bulk drugs/ intermediates by 18.85 TPA to 255.88 TPA. In April 2006, the company inaugurated their new manufacturing facilities at Baddi in Himachal Pradesh to manufacture tablets, injectibles and liquids.

During the year 2007-08, the company broadened its footprint operations into into the field of Phytochemicals, where, the company has put to operation a new manufacturing facility to manufacture mint-based products. They increased the production capacity of bulk drugs/ intermediates by 162.30 TPA to 418.18 TPA.